Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "Intravenous Immunoglobulins" patented technology

Immune globulin products from human plasma were first used in 1952 to treat primary immune deficiency. Intravenous immunoglobulin (IVIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors.

Affinity purified human polyclonal antibodies and methods of making and using them

InactiveUS20100150942A1Antibody ingredientsImmunoglobulinsBacteroidesAffinity purified antibody
The present invention describes a method for treating, removing or preventing a bacterial infection, which method comprises administering to a human suffering, suspected of suffering or at risk of suffering from Staphylococcus aureus (S. aureus) infection, a Streptococcus infection, Escherichia coli (E. coli) infection, Pseudomonas aeruginosa (P. aeruginosa) infection, Acinetobacter baumannii (A. baumannii) infection, Enterococcus faecium (E. faecium) infection and / or Clostridium difficile (C. difficile) infection, an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from bacterial cells selected from S. aureus, a Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, and optionally, wherein said affinity purified human polyclonal antibodies are purified (e.g., as made more concentrated as compared to the starting or unpurified material) relative to the same human polyclonal antibodies in the unpurified or non-affinity-purified human blood sample, e.g., intravenous immunoglobulin (IVIG) sample, and / or also optionally, wherein said affinity purified human polyclonal antibodies are specific for the bacterial antigens used in the affinity purification, and / or further optionally wherein the affinity purified human polyclonal antibodies are substantially free of human antibodies that specifically bind to non-bacterial antigens in the human blood sample. Pharmaceutical compositions for treating bacterial infections, comprising an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from S. aureus, Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, are also provided.
Owner:SCANTIBODIES LAB

Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods

A method of providing an immunotherapy treatment to a patient includes determining a level of C1 esterase inhibitor or inhibitor activity in the patient, determining an intravenous immunoglobulin dosing protocol for the patient based on the level of C1 esterase inhibitor or inhibitor activity, and administering the immunotherapy treatment to the patient.
Owner:MELAMED ISAAC

ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE

InactiveUS20130177574A1Market price thereof has been risingMinimizing IVIg related side effectAntipyreticAnalgesicsDiseaseAntigen
Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and / or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
Owner:RAVINDRANATH MEPUR DR

Method for preparing intravenous immunoglobulin

ActiveCN104479011ASolve the technical problems of low purity and high content of polymersReduce drug riskSerum immunoglobulinsPeptide preparation methodsPharmacyUltrafiltration
The invention provides a method for preparing the intravenous immunoglobulin. The method particularly includes the steps of dissolving component I+II+III or component II+III sediments; separating component I+III-1 or component III-1 sediments; separating component I+III-2 or component III-2 sediments; separating component II sediments; dissolving and filtering the component II sediments; conducting ultrafiltration, dialyzing and concentrating; conducting purification and filtering; conducting ultrafiltration dialysis, concentrating and preparation. By means of the method, steps and step parameters of the traditional process method are improved, specific combinations of the steps and the step parameters can be used for effectively extracting the human immunoglobulin for the intravenous injections from the component I+II+III or component II+III sediments, the technical problems that the human immunoglobulin for the intravenous injections is low in purity, and the content of polymer and the like is slightly high are solved, the pharmacy risk of people is reduced, and the pharmacy safety of people is guaranteed.
Owner:SHENZHEN WEIGUANG BIOLOGICAL PROD

Products for prophylaxis and/or treatment of viral diseases and methods of making and using same

The invention relates to an immunoglobulin composition suitable for prophylaxis and / or treatment of a viral mediated disease, disorder or condition and to methods of its preparation. In one embodiment, the invention provides a potent intravenous immunoglobulin composition useful for the treatment or prevention of a West Nile virus mediated disease, disorder or condition.
Owner:OMRIX BIOPHARM

Method for purifying immunoglobulin

The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dissolving immunoglobulin-containing plasma protein fraction I+II+III or fraction II+III; adding caprylate to the solution to cause precipitation; performing dialysis and concentration after removal of the precipitate; performing anion exchange resin and ceramic cation exchange resin purification processes to effectively remove a solvent and detergent added to inactivate viruses; and performing elution while maintaining salt concentration at a constant level to maintain the immunoglobulin polymer content at a low level. According to the method for preparing the intravenous immunoglobulin according to the present invention, a precipitation step of preparing fraction II from fraction I+II+III or fraction II+III as a starting material can be omitted, and problems, including a complicated process and a low yield, which occur in the conventional preparation process employing the polyethylene glycol treatment process, can be solved by use of first sodium caprylate precipitation, anion exchange chromatography and cation exchange chromatography. In addition, when the immunoglobulin purification method according to the present invention is used, the efficiency with which impurities and thrombotic substances are removed can be increased and the immunoglobulin polymer content can be maintained, and thus a stable immunoglobulin with increased quality can be produced.
Owner:GREEN CROSS HLDG

Method for detecting activated blood coagulation factor XI in human intravenous immunoglobulin

ActiveCN103185710AAvoid preactivationIndirectly reflect changes in production contentFluorescence/phosphorescenceInitiation factorFactor ii
The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.
Owner:BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI +1

Method for preparing immunoglobulin G by rapidly extracting plasma of COVID-19 patient in rehabilitation period

The invention relates to a method for preparing immunoglobulin G by rapidly extracting plasma of a COVID-19 patient in a rehabilitation period, and more particularly, to a method for preparing intravenous injection COVIDI-19 immunoglobulin G by rapidly separating component plasma from whole blood by using a closed multicellular component automatic separation system (MACSS), for example, to prepareintravenous injection superimmunoglobulin. The intravenous immunoglobulin can be used for treating patients infected by novel coronavirus. The method comprises the following steps: separating human peripheral blood into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, and then carrying out virus inactivation on the obtained plasma to obtain plasma capable of being used for preparing intravenous immunoglobulin G. The invention also relates to a method for preparing an intravenous immunoglobulin G preparation by using the plasma component obtained by the above method. According to the method, the plasma obtaining speed is high, and the antibody titer of the prepared plasmaand intravenous immunoglobulin G is high.
Owner:深圳博雅感知药业有限公司

Protein protective agent for Pasteur inactivating human intravenous immunoglobulin and inactivation method of protein protective agent

ActiveCN103550780AExtensive inactivationProtect proteinAntibody ingredientsPharmaceutical non-active ingredientsWater bathsGlycine
The invention provides a protein protective agent for Pasteur inactivating human intravenous immunoglobulin and an inactivation method of the protein protective agent. A Pasteur inactivation method of human intravenous immunoglobulin comprises the following steps of adding the protein protective agent to a human intravenous immunoglobulin solution before inactivating; adjusting the content of sampled protein to be 40 to 60g / L, and adjusting pH (Potential of Hydrogen) to be 4.7 to 5.3; agitating for 30 minutes; transferring into a water bath under 60+ / - 1 DEG C; maintaining the solution at temperature of 60+ / -0.5 DEG C for 10 hours after the solution temperature reaches 60 DEG C, thus accomplishing the inactivation of human intravenous immunoglobulin, wherein the protein protective agent is saccharose, arginine, glycine and sorbitol which are respective 50 to 70g / L, 20 to 40g / L, 30 to 60g / L and 240 to 260g / L in final content. According to the protein protective agent, simple sorbitol is used as the protective agent, the content of a polymer is decreased from 4.12% to 1.96%, thus the protein can be protected well, and the product quality can be improved.
Owner:BANGHE PHARMA CO LTD

Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma

The invention relates to an integrated scheme for fractionation and purification of plasma products (human albumin, intravenous immunoglobulin (IVIG), clotting factor VIII and clotting factor IX) by sequential chromatography and virus reduction steps. The therapeutically administrable protein IVIG has purity levels exceeding 98%, aggregates and dimers at less than 0.2%, Fc function of >90% and anti-complementary activity of less than 0.5 CH50 per mg of Ig. The distribution of IgG isomers is comparable to the ranges seen in normal plasma. Human albumin for therapeutic use, purified by this integrated scheme has an electrophoretic purity of close to 100%, with monomers exceeding 98%. The levels of aluminium and pre-kallikrein activator are below the detection limit for the respective tests. The Factor IX preparations have a specific activity of ≧200 IU / mg. The impurity levels of Factor-II, Factor VII, Factor X are at least 10-fold lesser (≦0.5% instead of 5%) and the heparin impurity of ≦0.01 IU (against 0.5 IU limit for this impurity) is 50-fold lesser the specified pharmacopoeial limits.The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence.
Owner:ICHOR BIOLOGICS PTE LTD

Treatment of diabetes mellitus

The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.
Owner:LEVIT EYAL

Method for rapidly extracting plasma of COVID-19 patient in rehabilitation period by automatic separation system

The invention relates to a method for rapidly extracting plasma of a COVED-19 patient in a rehabilitation period by an automatic separation system. The method comprises the following steps of: separating peripheral blood taken from a human body into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, performing virus inactivation on the obtained plasma, and optionally cryopreserving the plasma to obtain the plasma which can be used for preparing intravenous immunoglobulin G. Theinvention also comprises a method for preparing an intravenous immunoglobulin G preparation. The method comprises the following steps: obtaining a plasma component by the method, precipitating the plasma by a low-temperature ethanol method to obtain components I + II + III, separating a component II from a component I + III, respectively preparing an immunoglobulin G semi-finished product 1 and animmunoglobulin G semi-finished product 2, performing sterilization and virus inactivation to obtain an immunoglobulin G stock solution. and further preparing the intravenous immunoglobulin G preparation for intravenous injection. The method provided by the invention achieves excellent technical effects as described in the specification.
Owner:深圳博雅感知药业有限公司

A method of manufacturing intravenous immunoglobulin from fraction iii

The present subject matter is directed to a method of manufacturing purified IVIG from Fraction III of plasma, comprising re-constituting a Fraction III paste in a buffer; adjusting the pH and temperature; adding ethanol and then gradually lowering the temperature; centrifuging and filtering the supernatant; ultra-filtrating to remove alcohol; undergoing weak anion exchange chromatography; ultra-filtrating to reach a desired protein concentration; aseptic filtrating; nano filtrating for virus removal; and incubating at low pH for virus inactivation to obtain a resulting Fraction III suspensioncomprising purified IVIG. The present subject matter is directed to IVIG having 14 newly-found proteins, namely KH 26, KH 27, KH 28, KH 29, KH 30, KH 31, KH 32, KH 33, KH 39, KH 40, KH 41, KH 42, KH43, and KH 44 for both liquid and lyophilized form.
Owner:K 黄

Monomeric proteins and uses thereof

Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and / or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use.
Owner:UNIV OF LIVERPOOL +1

A kind of production technology of intravenous immunoglobulin

The invention provides a production process for intravenous immunoglobulin, which comprises separating the components I+II+III / II+III from healthy human plasma; Through the following chromatography: anion chromatography A, anion chromatography B, affinity chromatography C; after chromatography, the washing solution is prepared by ultrafiltration, concentration or dilution, and then filtered through a nano-membrane, incubated at a low pH value, and incubated After release, the solution is mixed, prepared and sterilized to obtain immunoglobulin for intravenous injection. The production process provided by the present invention can obtain IgG products with high yield and purity, and more importantly, the anti-A, anti-B indexes and ACA indexes of the obtained products are all greatly reduced, which meets the requirements of "Chinese Pharmacopoeia" well , and the osmolarity of the sample also meets the requirements very well.
Owner:SICHUAN YUANDASHUYANG PHARM CO LTD

DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRll/FcyRlll GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES

The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII / FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory FcγR; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.
Owner:STICHTING SANQUIN BLOEDVOORZIENING

System and device for predicting resistance of child suffering Kawasaki disease after first injection of intravenous immunoglobulin

The invention belongs to the technical field of Kawasaki disease medical equipment, and particularly discloses a system and device for predicting the resistance of child suffering Kawasaki disease after first injection of intravenous immunoglobulin, the prediction system comprises: a data acquisition module which is used for acquiring baseline data, image data and laboratory data of a sample before first IVIG treatment; a data processing module which is used for receiving and processing the data information acquired by the data acquisition module and acquiring variable parameters; a risk factor acquisition module which is used for receiving the variable parameters and screening to obtain IVIG resistance risk factors; and the prediction module which is used for bringing the IVIG resistance risk factors into a machine learning model and establishing a prediction model. According to the technical scheme, through cooperation of all the modules, collection and screening of sample information are achieved, and whether a child patient has first dose IVIG resistance or not is predicted according to the acquired information.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1

The invention relates to an application of intravenous immunoglobulins (IVIg) in preparing a medicament for treating autoimmune diseases of a peripheral nervous system, the autoimmune diseases are related ganglioside GM1 antibody diseases, and the IVIg is used for treating the related ganglioside GM1 antibody diseases by inhibiting cholera toxin and galectin from being combined into ganglioside GM1. The advantages are as follows: the research finds that the IVIg can not inhibit the combination of the GM1 antibody with the antigen thereof and the GM1 antibody titer is not reduced, the inhibition of the IVIg on the combination of the cholera toxin and galectin into the GM1 can be displayed; and put forward in a first time, galactosyl / non-galactosyl immune globulin with correction rate in the IVIg are mutually acted on a macrophage receptor, so that the inflammation functions of autoimmune disease of macrophage and a peripheral nervous system can be reduced.
Owner:CENT HOSPITAL XUHUI DISTRICT SHANGHAI CITY

Process of cloning and further purification to make a recombinant intravenous immunoglobulin

The present subject matter is directed to a process of cloning and purifying recombinant intravenous immunoglobulin (IVIG), comprising cloning a target gene of human immunoglobulin; in vitro screeningof a yeast cell expressing the target gene of human immunoglobulin to create a yeast cell line; fermenting the yeast cell line and collecting a resulting culture medium; filtering the culture medium;undergoing weak anion exchange chromatography to collect a flow-through solution; ultra-filtrating the flow-through solution to reach a desired protein concentration; aseptic filtrating the flow-through solution; nano-filtrating the flow-through solution for virus removal; and filling and incubating the flow-through solution at low pH for virus inactivation to obtain a purified recombinant IVIG.The present subject matter is directed to purified recombinant IVIG having five newly-found proteins, namely KH 33, KH 34, KH 35, KH 36, and KH 37 for both liquid and lyophilized forms.
Owner:K 黄

Compositions for expanding regulatory t cells (TREG), and treating autoimmune and inflammatory diseases and conditions

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (WIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products